Sentinel Solid — Monitoring solid tumours on treatment.
SENTINEL · MONITORING SOLID TUMOURS ON TREATMENT
Sentinel Solid is continuous monitoring for solid tumours during active treatment for advanced disease. From repeat blood draws, it tracks ctDNA to show whether therapy is working and to catch molecular progression or resistance early — often before imaging reveals the cancer moving.
2 · What it watches for
Sentinel Solid tracks the signals that matter most during active treatment.
Response
Falling ctDNA as an early sign the current therapy is working.
Molecular progression
A rising trend that can precede radiographic progression.
Resistance mutations
New changes that let the cancer escape the current drug, so a switch can be planned in time.
3 · The Sentinel Alert workflow
From signal to action — fast.
Red flag
A rising ctDNA trend or new resistance mutation on a scheduled draw.
Clinical briefing
KPCIRC reviews it in the context of your treatment.
Counter-attack
Evidence-based next options are surfaced — switch, combination, or trial.
Seamless transition
Your navigator helps you move to the next line without delay.
4 · Why it needs a baseline
Tracking works best against a molecular fingerprint.
A baseline profile (for example Signature STb O, 118 genes) establishes what to follow, so later draws can be compared meaningfully and resistance spotted early.
5 · Honest limits. Sentinel Solid can provide valuable lead time, but sensitivity depends on ctDNA shedding, and monitoring supports — it does not replace — scans and specialist judgement. Every treatment change is decided by KPCIRC clinicians with you.
TERMINOLOGY ON THIS PAGE
The words you will see, in plain language
Sentinel Solid is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Need a second opinion or professional feedback?
If you want an independent clinical view — or you are a clinician seeking a molecular tumour board discussion — our exclusive clinical partner KPCIRC provides paid second opinions, molecular tumour board reviews, and genetic counselling. Ask your navigator, or request it from any page.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →